288 results match your criteria: "University of California San Diego Moores Cancer Center[Affiliation]"

Background: Measures to control COVID-19 transmission disrupted childhood cancer care. Data on the effects of the COVID-19 pandemic on childhood cancer mortality are lacking. This study describes the impact of the pandemic on childhood cancer early-mortality (≤ 24 months).

View Article and Find Full Text PDF

We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study. Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of , , , , , , , or received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).

View Article and Find Full Text PDF

Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy.

Methods: We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial.

View Article and Find Full Text PDF
Article Synopsis
  • Dual inhibition using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) was tested on patients with desmoid tumors in a phase II clinical trial to assess efficacy and safety in treating these rare solid tumors.
  • The study involved 16 patients, with an overall response rate (ORR) of 18.8%, and a clinical benefit rate (CBR) of 62.5%, indicating decent stability and response to treatment over an average of 19.4 months of progression-free survival (PFS).
  • Adverse events were common, with fatigue, nausea, and hypothyroidism reported, highlighting the need for careful monitoring during treatment.
View Article and Find Full Text PDF

Objectives: MET exon 14 skipping alterations (METex14+) represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) with distinct biological and genomic features. We characterized this heterogeneity in a large cohort, integrating genomic and transcriptomic profiling with clinical outcomes, to elucidate the histologic and molecular traits and survival patterns of METex14+ NSCLC.

Materials And Methods: NSCLC tissue samples (n = 28,739) underwent DNA-based next-generation sequencing (592 genes, NextSeq) or whole-exome sequencing (NovaSeq), RNA-sequencing including whole transcriptome sequencing (WTS, NovaSeq), and PD-L1 IHC (Dako 22C3) at Caris Life Sciences.

View Article and Find Full Text PDF

Background: Increasing representation in clinical trials is a priority for the National Cancer Institute and Children's Oncology Group (COG). Our survey of COG-affiliated institutions revealed that many sites have insufficient processes and resources to enroll children whose parents use languages other than English (LOE). We describe reported barriers and facilitators to enrolling children in clinical trials when parents use LOE and propose opportunities for improvement.

View Article and Find Full Text PDF

Proceedings of the 1st biannual bridging the gaps in lung cancer conference.

Oncologist

September 2024

Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, United States.

Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers.

View Article and Find Full Text PDF

Bakground: It is important to understand the outcomes of adult acute lymphoblastic leukemia (ALL) patients at different facilities as treatment paradigms change.

Aims: Our primary objective was to determine adult ALL overall survival (OS) by facility volume and type. Secondary objectives included identifying sociodemographic factors that may have impacted outcomes and analyzing treatment patterns by facility volume and type.

View Article and Find Full Text PDF

Introduction: Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, and germline-controlled ctDNA levels were quantified and analyzed in patients with PDAC. Plasma samples (n = 1329) from 298 clinically validated patients were collected at diagnosis, perioperatively (MRD-window; within 2-12 weeks after surgery, before therapy), and during surveillance (>12 weeks post-surgery if no ACT or starting 4 weeks post-ACT) from November 2019 to March 2023.

View Article and Find Full Text PDF
Article Synopsis
  • Myelodysplastic syndromes (MDS) are blood disorders marked by irregularities in myeloid cells and low blood cell counts, often caused by genetic mutations, though classification has mostly focused on cell appearance.
  • A study analyzing genomic data from over 3,200 MDS patients identified 16 distinct molecular subtypes, revealing varied clinical outcomes, with the majority of patients (86%) fitting into specific genetic groups linked to different survival rates.
  • The findings suggest that understanding these genetically defined subgroups can enhance MDS classification and inform future treatment strategies, emphasizing the importance of genetic insight in managing the disease.
View Article and Find Full Text PDF

KRAS G12C inhibitor combination therapies: current evidence and challenge.

Front Oncol

May 2024

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Although KRAS G12C inhibitors have proven that KRAS is a "druggable" target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS G12C inhibitors with other targeted therapies, such as RTK, SHP2, and MEK inhibitors, have been investigated in clinical trials to overcome the resistance. They have demonstrated promising efficacy especially by combining KRAS G12C and EGFR inhibitors for KRAS G12C-mutated colorectal cancer.

View Article and Find Full Text PDF

Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions.

View Article and Find Full Text PDF

Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.

Nat Commun

April 2024

Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Genome-wide association studies (GWAS) have identified more than 200 common genetic variants independently associated with colorectal cancer (CRC) risk, but the causal variants and target genes are mostly unknown. We sought to fine-map all known CRC risk loci using GWAS data from 100,204 cases and 154,587 controls of East Asian and European ancestry. Our stepwise conditional analyses revealed 238 independent association signals of CRC risk, each with a set of credible causal variants (CCVs), of which 28 signals had a single CCV.

View Article and Find Full Text PDF

Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.

J Gastrointest Surg

March 2024

Section of Hematology/Oncology, Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States.

Background: Sarcopenic obesity and muscle attenuation have been associated with survival in patients with borderline resectable and advanced pancreatic ductal adenocarcinoma (PDA); however, these relationships are unknown for patients with resectable PDA. This study examined the associations between skeletal muscle and adipose tissue as measured on baseline computed tomography (CT) and the overall survival (OS) of participants with resectable PDA in a secondary analysis of the Southwest Oncology Group S1505 clinical trial (identifier: NCT02562716).

Methods: The S1505 phase II clinical trial enrolled patients with resectable PDA who were randomized to receive modified FOLFIRINOX or gemcitabine and nab-paclitaxel as perioperative chemotherapy, followed by surgical resection.

View Article and Find Full Text PDF

Background: There exist few maximal oxygen uptake (VO) non-exercise-based prediction equations, fewer using machine learning (ML), and none specifically for older adults. Since direct measurement of VO is infeasible in large epidemiologic cohort studies, we sought to develop, validate, compare, and assess the transportability of several ML VO prediction algorithms.

Methods: The Baltimore Longitudinal Study of Aging (BLSA) participants with valid VO tests were included (n = 1080).

View Article and Find Full Text PDF
Article Synopsis
  • The purpose of this guideline is to provide updated, evidence-based treatment recommendations for patients with stage IV non-small cell lung cancer (NSCLC) who do not have specific genetic driver alterations.
  • The recommendations are based on recent systematic reviews and randomized clinical trials, focusing on both efficacy and safety, and were developed by an Expert Panel with diverse expertise.
  • The latest update identified ten new randomized clinical trials and consolidates previous recommendations, covering treatment options for first, second, and subsequent lines of therapy.
View Article and Find Full Text PDF
Article Synopsis
  • The guideline aims to provide evidence-based recommendations for treating stage IV non-small cell lung cancer patients with specific driver alterations.
  • It is regularly updated based on systematic reviews of clinical trials, with the latest review covering studies from February to October 2023.
  • The latest update identified eight new randomized controlled trials and refined treatment recommendations for different stages of therapy based on targetable driver alterations.
View Article and Find Full Text PDF

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.

Surg Oncol Clin N Am

April 2024

Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Froedtert and Medical College of Wisconsin Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA; WIN Consortium, Paris, France; University of Nebraska, Lincoln, NE, USA.

With multiple molecular targeted therapies available for patients with cancer that correspond to a specific genetic alteration, the selection of the best treatment is essential to ensure therapeutic efficacy. Molecular tumor boards (MTBs) play a key role in this process to deliver personalized medicine to patients with cancer in a multidisciplinary manner. Historically, personalized medicine has been offered to patients with advanced cancer, but the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB.

View Article and Find Full Text PDF

Introduction: Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open-label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer.

View Article and Find Full Text PDF
Article Synopsis
  • * Multi-omics analyses of blood and tissue samples from a clinical trial revealed that higher immune scores correlate with better responses to ICIs, while certain immune cells, like regulatory T cells, negatively impact survival.
  • * Variations in immune cell density and proximity to tumor cells influence survival outcomes, and soluble proteins found in the blood could serve as indicators for treatment effectiveness and overall survival in SqNSCLC patients.
View Article and Find Full Text PDF

Unlabelled: Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.

View Article and Find Full Text PDF

Importance: Ensuring valid informed consent (IC) prior to enrollment in clinical trials is a fundamental ethical right.

Objective: To assess whether social determinants of health (SDOH) and related sociocontextual factors are associated with parental IC comprehension in therapeutic childhood cancer clinical trials.

Design, Setting, And Participants: This cross-sectional study prospectively enrolled 223 parents of children with newly diagnosed cancer at Rady Children's Hospital San Diego, a large quaternary academic center in California, from October 1, 2014, to March 31, 2021.

View Article and Find Full Text PDF

What Is This Summary About?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder.

What Were The Results?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects.

View Article and Find Full Text PDF